As filed with the Securities and Exchange Commission
on April 5, 2022.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Longeveron Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
47-2174146 |
|
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. employer
identification number) |
1951 NW 7th Avenue, Suite 520
Miami, Florida 33136
(305) 909-0840
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Geoff Green
Chief Executive Officer
Longeveron Inc.
1951 NW 7th Avenue, Suite 520
Miami, Florida 33136
(305) 909-0840
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Copies to:
Jennifer R. Minter, Esq. and Brian North, Esq.
Buchanan Ingersoll & Rooney PC
Union Trust Building
501 Grant Street, Suite 200
Pittsburgh, PA 15219
(412) 562-8800
Approximate date of commencement of proposed sale
to the public: From time to time after the effective date of this registration statement as determined by the Registrant.
If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check
the following box. ☐
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 of the Securities
Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, please check the following box. ☐
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional
securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, please check the following box. ☐
Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and
“emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer ☐ Accelerated
filer ☐ Non-accelerated
filer ☒ Smaller
reporting company ☒ Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐
The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act or until this Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
THE INFORMATION IN THIS PROSPECTUS
IS NOT COMPLETE AND MAY BE CHANGED. WE MAY NOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES
IN ANY JURISDICTION WHERE THE OFFER OR SALE IS NOT PERMITTED.
| Prospectus |
|
Subject to Completion, Dated April 5, 2022 |
$50,000,000
Class A Common Stock
Preferred Stock
Warrants
Purchase Contracts
Units
We may offer and sell, from time to time in one or
more offerings, any combination of the securities identified above in one or more offerings, having a maximum aggregate offering price
of $50,000,000. This prospectus provides you with a general description of the securities. When we decide to sell a particular class or
series of securities, we will provide specific terms of the offered securities in a prospectus supplement.
Each time we offer and sell securities, we will provide
a supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities.
The supplement may also add, update or change information contained in this prospectus with respect to that offering. You should carefully
read this prospectus and the applicable prospectus supplement, together with any documents we incorporated by reference, before you invest
in any of our securities.
We are an emerging growth company and a smaller
reporting company as defined under Federal securities laws and, as such, may elect to comply with certain reduced public company reporting
requirements for future filings.
Our common stock is traded on NASDAQ Capital Market
under the symbol “LGVN.” Each prospectus supplement will contain information, where applicable, as to our listing on NASDAQ
Capital Market or any other securities exchange of the securities covered by the prospectus supplement. On April 1, 2022, the last reported
sale price of our common stock on the NASDAQ Capital Market was $15.61. As of April 4, 2022, the aggregate market value of our outstanding
common stock held by non-affiliates was approximately $72.5 million, which we calculated based on 5,326,512 shares of outstanding common
stock as of March 31, 2022, of which 4,642,545 shares were held by non-affiliates, and a price per share of $15.61 as of April 1, 2022,
which is a date within 60 days prior to the filing date of this prospectus. Pursuant to General Instruction I.B.6 of Form S-3, in no event
will we sell, pursuant to the registration statement of which this prospectus forms a part, securities with a value exceeding one-third
of the aggregate market value of our outstanding common stock held by non-affiliates in any 12-month period, so long as the aggregate
market value of our outstanding common stock held by non-affiliates remains below $75.0 million. During the 12 calendar months prior to
and including the date of this prospectus, we have not offered or sold any securities pursuant to General Instruction I.B.6 of Form S-3.
These securities may be sold directly by us, through
dealers or agents designated from time to time, to or through underwriters or through a combination of these methods. See “Plan
of Distribution” in this prospectus. We may also describe the plan of distribution for any particular offering of our securities
in a prospectus supplement. If any agents, underwriters or dealers are involved in the sale of any securities in respect of which this
prospectus is being delivered, we will disclose their names and the nature of our arrangements with them in a prospectus supplement. The
net proceeds we expect to receive from any such sale will also be included in a prospectus supplement.
Investing in our securities involves a high degree
of risk. See “Risk Factors” on page 4 for more information on these risks. Additional risks, if any,
will be described in the prospectus supplement related to a potential offering under the heading “Risk Factors” and in our
filings with the Securities and Exchange Commission that are incorporated by reference in this prospectus. You should review that section
of the related prospectus supplement and those filings for a discussion of matters that investors in such securities should consider.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus
or any accompanying prospectus supplement. Any representation to the contrary is a criminal offense.
The date of this Prospectus is ,
2022
TABLE OF CONTENTS
ABOUT
THIS PROSPECTUS
This prospectus is part of a registration statement
that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process. Under
this shelf registration process, we may offer from time to time any combination of the securities described in this prospectus having
a maximum aggregate offering price of $50,000,000. Each time we offer securities, we will prepare and file with the SEC a prospectus supplement
that describes the specific amounts, prices and terms of the securities we offer. We may also authorize one or more free writing prospectuses
to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus
may also add, update or change information contained in this prospectus with respect to that offering.
To the extent there is a conflict between the information
contained in this prospectus, on the one hand, and the information contained in any prospectus supplement or in any document incorporated
by reference in this prospectus, on the other hand, you should rely on the information in this prospectus, provided that if any statement
in one of these documents is inconsistent with a statement in another document having a later date — for example,
a prospectus supplement or a document incorporated by reference in this prospectus — the statement in the document
having the later date modifies or supersedes the earlier statement.
Before buying any of the securities that we are offering,
you should carefully read both this prospectus and any prospectus supplement with all of the information incorporated by reference in
this prospectus, as well as the additional information described under the heading “Where You Can Find More Information About Us”
and “Incorporation of Certain Documents by Reference.” These documents contain important information that you should consider
when making your investment decision. We have filed or incorporated by reference exhibits to the registration statement of which this
prospectus forms a part. You should read the exhibits carefully for provisions that may be important to you.
You should rely only on the information contained
or incorporated by reference in this prospectus or any prospectus supplement. We have not authorized any other person to provide you with
different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus is
not an offer to sell securities, and it is not soliciting an offer to buy securities, in any jurisdiction where the offer or sale is not
permitted. You should assume that the information appearing in this prospectus or any prospectus supplement (or any free writing prospectus),
as well as information we have previously filed with the SEC and incorporated by reference, is accurate as of the date of those documents
only. Our business, financial condition, results of operations and prospects may have changed since those dates.
We may sell securities through underwriters or dealers,
through agents, directly to purchasers or through any combination of these methods. We and our agents reserve the sole right to accept
or reject in whole or in part any proposed purchase of securities. The prospectus supplement, which we will prepare and file with the
SEC each time we offer securities, will set forth the names of any underwriters, agents or others involved in the sale of securities,
and any applicable fee, commission or discount arrangements with them. See “Plan of Distribution.”
Unless otherwise indicated in this prospectus or the
context otherwise requires, all references to “we,” “us,” “our,” “the Company” and “Longeveron”
refer to Longeveron Inc. Longeveron has no subsidiaries. When we refer to “you,” we mean the holders of the applicable series
of securities.
PROSPECTUS SUMMARY
The following summary, because it is a summary, may
not contain all the information that may be important to you. This prospectus incorporates important business and financial information
about the Company that is not included in, or delivered with, this prospectus. Before making an investment, you should read the entire
prospectus and any supplements or amendments carefully. You should also carefully read the risks of investing discussed under “Risk
Factors” and the financial statements included in our other filings with the SEC, including in our Annual Report on Form 10-K for
the fiscal year ended December 31, 2021, which we filed with the SEC on March 11, 2022, and any of our other subsequently filed periodic
reports on Form 10-Q. This information is incorporated by reference into this prospectus, and you can obtain it from the SEC as described
below under the headings “Where You Can Find Additional Information About Us” and “Incorporation of Certain Documents
by Reference.”
Upon request, we will provide to each person, including any beneficial
owner, to whom a prospectus is delivered, a copy of any or all of the information that has been incorporated by reference in the prospectus
but not delivered with the prospectus. You may request a copy of these filings, excluding the exhibits to such filings which we have not
specifically incorporated by reference in such filings, at no cost, by writing us at the following address: Longeveron Inc., 1951 NW 7th
Avenue, Suite 520, Miami, Florida 33136, Attention: Legal Department.
THE SECURITIES THAT MAY BE OFFERED
We may offer or sell common stock, preferred stock,
warrants, purchase contracts and units in one or more offerings and in any combination. The aggregate offering price of the securities
we sell pursuant to this prospectus will not exceed $50,000,000. Each time securities are offered with this prospectus, we will provide
a prospectus supplement that will describe the specific amounts, prices and terms of the securities being offered and the net proceeds
we expect to receive from that sale.
The securities may be sold to or through underwriters,
dealers or agents or directly to purchasers or as otherwise set forth in the section of this prospectus captioned “Plan of Distribution.”
Each prospectus supplement will set forth the names of any underwriters, dealers, agents or other entities involved in the sale of securities
described in that prospectus supplement and any applicable fee, commission or discount arrangements with them.
OUR COMPANY
We are a clinical stage biotechnology
company developing cellular therapies for specific aging-related and life-threatening conditions. Our lead investigational product is
the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling
cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue
repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult disorders
associated with the aging process and other conditions.
We are currently sponsoring
or have sponsored Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease (AD), the Metabolic
Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Our mission is to advance Lomecel-B
and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization
and broad use by the healthcare community.
Our philosophy is that healthy
aging can be improved through regenerative medicine approaches. Life expectancy has substantially increased over the past century as a
result of medical and public health advancements. However, this increase in longevity has not been paralleled by the number of years a
person is expected to live in relatively good health, with limited chronic disease and disabilities of aging – a period known as
healthspan. As we age, we experience: a decline in our own stem cells; a decrease in immune system function, known as immunosenescence;
diminished blood vessel functioning; chronic inflammation, known as “inflammaging”; and other aging-related declines. Our
preliminary clinical data suggest that Lomecel-B can potentially address these problems through multiple mechanisms of action, or MOAs,
that simultaneously target key aging-related processes.
Improving healthspan is an
imperative for governmental health agencies. The National Institute on Aging (NIA), an institute of the National Institutes of Health
(NIH), has promoted the concept of geroscience – the idea that aging itself is the biggest risk factor for aging-related human diseases
and that aging can be approached as a treatable disease to improve healthspan. The geroscience hypothesis provides a strong rationale
for the approach of treating underlying biological processes contributing to aging as a way to reduce disease burden and advance global
human health. Our investments into developing and testing product candidates are aimed at reducing aging-related disease burden and improving
healthspan.
Our core business strategy
is to become a world leading regenerative medicine company through the development and commercialization of novel cell therapy products
for unmet medical needs, with emphasis on aging-related indications. Key elements of our business strategy are as follows.
| ● |
Advance Lomecel-B and other regenerative medicine products to market. We are advancing Lomecel-B into later stage clinical trials for the purpose of achieving commercialization in one or more indications. Our studies throughout the clinical development process are intended to generate safety and efficacy data needed to advance these programs, and establish foundations for subsequent development and expansion into new areas. We will continue to leverage our technical and clinical expertise, and relationships with clinical investigators, treatment centers, and other key stakeholders, to explore new opportunities. |
| |
|
| ● |
Expand our manufacturing capabilities to commercial-scale production. We operate a good manufacturing practice (GMP) – compliant manufacturing facility and produce our own product candidates for testing. We continue to improve and expand our capabilities with the goal of achieving cost-effective large-scale manufacturing to meet future commercial demand. |
| |
|
| ● |
Non-dilutive funding. Our clinical programs have received over $16.0 million in competitive extramural grant awards ($11.9 million which has been directly awarded to us and which are recognized as revenue when the performance obligations are met) from the NIH, Alzheimer’s Association, and Maryland Stem Cell Research Fund (MSCRF). These prestigious funding awards are non-dilutive and allow us to collaborate with state and federal partners in pursuing safe and effective therapeutics for disorders that have few, if any, available approved treatments. |
| ● |
Continue to develop our existing international programs. We have selected Japan as our first non-U.S. territory for a randomized, double-blinded, placebo-controlled clinical trial to evaluate Lomecel-B for Aging Frailty. We intend to explore other indications and other international locations for further development and commercialization. |
| ● |
Collaboration arrangements and out-licensing opportunities. We will be opportunistic and consider entering into co-development, out-licensing, commercialization or other collaboration agreements for the purpose of commercializing Lomecel-B and other products domestically and internationally. |
| |
|
| ● |
Product candidate development pipeline through internal research and development, and in-licensing. Through our research and development program, and through strategic in-licensing agreements, or other business development arrangements, we continue to actively explore promising potential additions to our pipeline of product candidates. |
| |
|
| ● |
Continue to expand our intellectual property portfolio. Our intellectual property is vitally important to our business strategy, and we take significant steps to develop this property and protect its value. Results from our ongoing research and development efforts are intended to add to our existing intellectual property portfolio. |
Emerging Growth Company
We are an “emerging growth company” as
defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. We will remain an emerging growth company until
the earlier of (1) December 31, 2026, (2) the last day of the fiscal year in which we have total annual gross revenues of at
least $1.07 billion, (3) the date on which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2
under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which would occur if the market value of our Common
Stock held by non-affiliates exceeded $700.0 million as of the last business day of our most recently completed second fiscal quarter
or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year
period. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant
requirements that are otherwise generally applicable to public companies. As an emerging growth company we may (i) reduce our executive
compensation disclosure; (ii) present only two years of audited financial statements, plus unaudited condensed financial statements
for any interim period, and related Management’s Discussion and Analysis of Financial Condition and Results of Operations in this
Prospectus; (iii) avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on
the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; and (iv) not require
stockholder non-binding advisory votes on executive compensation or golden parachute arrangements.
We have availed ourselves in this prospectus of the
reduced reporting requirements described above. As a result, the information that we provide stockholders may be less comprehensive than
what you might receive from other public companies. When we are no longer deemed to be an emerging growth company, we will not be entitled
to the exemptions provided in the JOBS Act discussed above. We have elected to avail ourselves of the exemption that allows emerging growth
companies to extend the transition period for complying with new or revised financial accounting standards. This election is irrevocable.
We are also currently a “smaller reporting company,”
meaning that we are not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent company that is not
a smaller reporting company and have a public float of less than $250 million or annual revenues of less than $100 million during
the most recently completed fiscal year. In the event that we are still considered a “smaller reporting company,” at such
time as we cease being an “emerging growth company,” the disclosure we will be required to provide in our SEC filings will
increase, but will still be less than it would be if we were not considered either an “emerging growth company” or a “smaller
reporting company.” Specifically, similar to “emerging growth companies,” “smaller reporting companies”
are able to provide simplified executive compensation disclosures in their filings; are exempt from the provisions of Section 404(b)
of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide an attestation report on the effectiveness
of internal control over financial reporting; and have certain other decreased disclosure obligations in their SEC filings, including,
among other things, only being required to provide two years of audited financial statements in annual reports. Decreased disclosures
in our SEC filings due to our status as an “emerging growth company” or “smaller reporting company” may make it
harder for investors to analyze our results of operations and financial prospects.
Corporate Information
We were initially formed as a Delaware limited liability
company in October 2014, and as part of our initial public offering in February 2021, converted into a Delaware corporation pursuant to
a statutory conversion, and changed our name to Longeveron Inc. Our principal executive offices are located at 1951 NW 7th
Avenue, Suite 520, Miami, Florida 33136 and our telephone number is (305) 909-0840. Our website address is www.longeveron.com
and we make our filings with the Securities and Exchange Commission (SEC) available on the Investor Relations page of our website. The
reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not incorporated
into this prospectus or the registration statement of which it forms a part. Our Class A Common Stock is traded on the NASDAQ under the
symbol “LGVN.”
RISK FACTORS
Investing in our securities involves risk. The prospectus
supplement applicable to a particular offering of securities will contain a discussion of the risks applicable to an investment in the
Company and to the particular types of securities that we are offering under that prospectus supplement. Before making an investment decision,
you should carefully consider the risks described under “Risk Factors” in the applicable prospectus supplement and the risks
described in our most recent Annual Report on Form 10-K, or any updates thereto in our Quarterly Reports on Form 10-Q, together with all
of the other information appearing in or incorporated by reference into this prospectus and any applicable prospectus supplement or free
writing prospectus, in light of your particular investment objectives and financial circumstances. Our business, financial condition or
results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline
due to any of these risks, and you may lose all or part of your investment.
USE OF PROCEEDS
Except as otherwise provided in the applicable prospectus
supplement, we intend to use the net proceeds from the sale of the securities covered by this prospectus for general corporate purposes,
which may include, but is not limited to, working capital, capital expenditures, research and development expenditures, clinical trials,
third party collaborations and partnerships and acquisitions of new businesses. The precise amount, use and timing of the application
of such proceeds will depend upon our funding requirements and the availability and cost of other capital. Additional information on the
use of net proceeds from an offering of securities covered by this prospectus may be set forth in the prospectus supplement relating to
such offering.
FORWARD-LOOKING
STATEMENTS
This prospectus and the documents incorporated by
reference herein contain forward-looking statements. All statements other than statements of historical facts contained in this prospectus
and the documents incorporated by reference herein, including statements regarding our future results of operations and financial position,
business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development
costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are
forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some
cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking statements.
In some cases, you can identify forward-looking statements
by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,”
“anticipate,” “could,” “intend,” “target,” “project,” “believe,”
“estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other
similar expressions. Forward-looking statements contained in this prospectus and the documents incorporated by reference herein include,
but are not limited to, statements about:
| ● |
the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; |
| |
|
| ● |
the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; |
| |
|
| ● |
the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; |
| |
|
| ● |
the success of competing therapies that are or may become available; |
| |
|
| ● |
the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; |
| |
|
| ● |
our ability to obtain and maintain regulatory approval of our product candidates; |
| |
|
| ● |
our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue; |
| |
|
| ● |
existing regulations and regulatory developments in the United States, Japan and other jurisdictions; |
| |
|
| ● |
our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available, and our ability to avoid infringing the intellectual property rights of others; |
| |
|
| ● |
the need to hire additional personnel and our ability to attract and retain such personnel; |
| |
|
| ● |
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |
| |
|
| ● |
our need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; |
| |
|
| ● |
our financial performance; and |
| |
|
| ● |
the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements. |
We have based these forward-looking statements largely
on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe
may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees
of future performance or development. These forward-looking statements speak only as of the date of this prospectus and are subject to
a number of risks, uncertainties and assumptions described in the section titled “Risk Factors” and elsewhere in this prospectus
and the documents incorporated by reference herein. Because forward-looking statements are inherently subject to risks and uncertainties,
some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events.
The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update
or revise any forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information,
future events or otherwise.
In addition, statements that “we believe”
and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available
to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information
may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or
review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly
rely upon these statements.
This prospectus and the documents incorporated by
reference in this prospectus may contain market data that we obtain from industry sources. These sources do not guarantee the accuracy
or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information.
The market data may include projections that are based on a number of other projections. While we believe these assumptions to be reasonable
and sound as of the date of this prospectus, actual results may differ from the projections.
DESCRIPTIONS OF THE SECURITIES WE MAY OFFER
The descriptions of the securities contained in this
prospectus, together with any applicable prospectus supplement, summarize all the material terms and provisions of the various types of
securities that we may offer. We will describe in the applicable prospectus supplement or applicable free writing prospectus relating
to a particular offering the specific terms of the securities offered by that prospectus supplement (or free writing prospectus). We will
indicate in the applicable prospectus supplement (or free writing prospectus) if the terms of the securities differ from the terms we
have summarized below. We will also include in the prospectus supplement (or free writing prospectus) information, where applicable, about
material United States federal income tax considerations relating to the securities.
We may issue from time to time, in one or more offerings,
the following securities:
| ● |
shares
of Class A Common Stock, par value $0.001 per share, of the Company; |
| ● |
shares
of preferred stock, par value $0.001 per share, of the Company; |
| |
|
| ● |
warrants; |
| ● |
purchase
contracts; and |
| ● |
units
representing two or more of the foregoing securities. |
We will set forth in the applicable
prospectus supplement and/or free writing prospectus a description of any warrants, purchase contracts or units issued by us that may
be offered or sold pursuant to this prospectus. The terms of the offering of securities, the initial offering price and the net proceeds
to us will be contained in the prospectus supplement, and other offering material, relating to such offer.
DESCRIPTION OF CAPITAL STOCK
General
The following description of our Class A Common Stock,
together with the additional information we include in any applicable prospectus supplements (or free writing prospectus), summarizes
the material terms and provisions of the Class A Common Stock that we may offer under this prospectus. For the complete terms of our Class
A Common Stock, please refer to our certificate of incorporation and bylaws which are incorporated by reference into the registration
statement which includes this prospectus. The terms of our Class A Common Stock may also be affected by Delaware law.
Authorized Capital Stock
Our authorized capital stock consists of 84,295,000
shares of Class A Common Stock, par value $0.001 per share, 15,705,000 shares of Class B Common Stock, par value $0.001 per share
and 5,000,000 shares of preferred stock, par value $0.001 per share, the rights and preferences of which may be established from time
to time by our board of directors.
As of March 31, 2022 there were 5,326,512 shares of
our Class A Common Stock outstanding, held by approximately 13 stockholders of record, 15,585,062 shares of our Class B Common Stock
outstanding, held by approximately three stockholders of record, and no shares of our preferred stock outstanding.
Common Stock
We have two classes of authorized common stock, Class
A Common Stock and Class B Common Stock. The rights of the holders of Class A Common Stock and Class B Common Stock are identical,
except with respect to voting and conversion.
Voting. Holders of our Class A
Common Stock are entitled to one (1) vote for each share held on all matters submitted to a vote of stockholders and holders of our
Class B Common Stock are entitled to five (5) votes for each share of Class B Common Stock held on all matters submitted
to a vote of stockholders. The holders of our outstanding Class B Common Stock hold 93.6% of the voting power of our outstanding
capital stock. Holders of shares of our Class A Common Stock and Class B Common Stock vote together as a single class on all matters
(including the election of directors) submitted to a vote of stockholders, unless otherwise required by Delaware law or our certificate
of incorporation. Delaware law could require either holders of our Class A Common Stock or Class B Common Stock to vote separately
as a single class in the following circumstances:
| |
(1) |
if we were to seek to amend our certificate of incorporation to increase or decrease the par value of a class of our capital stock, then that class would be required to vote separately to approve the proposed amendment; and |
| |
|
|
| |
(2) |
if we were to seek to amend our certificate of incorporation in a manner that alters or changes the powers, preferences, or special rights of a class of our capital stock in a manner that affected its holders adversely, then that class would be required to vote separately to approve the proposed amendment. |
Our certificate of incorporation does not provide
for cumulative voting for the election of directors. As a result, the holders of a majority of the voting power of our outstanding capital
stock can elect all of the directors then standing for election. Our certificate of incorporation establishes a classified board of directors,
to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of
our stockholders, with the other classes continuing for the remainder of their respective three-year terms. An election of directors by
our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to
the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority
in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our certificate of incorporation
and bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds
in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders
of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal,
or to adopt any provision inconsistent with, several of the provisions of our certificate of incorporation.
Dividends. Holders of common stock
are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend
rights of any series of preferred stock that we may designate and issue in the future.
Liquidation. In the event of our liquidation
or dissolution, the holders of our Class A Common Stock and Class B Common Stock will be entitled to receive proportionately our net assets
available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any
outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights,
preferences and privileges of holders of common stock will be subject to and may be adversely affected by the rights of the holders of
shares of any series of preferred stock that we may designate and issue in the future.
Change of Control Transactions. In
the case of any distribution or payment in respect of the shares of our Class A Common Stock or Class B Common Stock upon a merger or
consolidation with or into any other entity, or other substantially similar transaction, the holders of our Class A Common Stock and Class
B Common Stock will be treated equally and identically with respect to shares of Class A Common Stock or Class B Common Stock owned by
them; provided, however, shares of each class may receive, or have the right to elect to receive, different or disproportionate consideration
if the only difference in the per share consideration is that the shares to be distributed to a holder of a share Class B Common Stock
have five (5) times the voting power of any securities distributed to a holder of a share of Class A Common Stock.
Subdivisions and Combinations. If
we subdivide or combine in any manner outstanding shares of Class A Common Stock or Class B Common Stock, the outstanding shares of the
other class will be subdivided or combined in the same manner, unless different treatment of the shares of each class is approved by the
affirmative vote of the holders of a majority of the outstanding shares of Class A Common Stock and Class B Common Stock, each voting
as a separate class.
Conversion. Each outstanding share
of Class B Common Stock is convertible at any time at the option of the holder into one share of Class A Common Stock. In addition, each
share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon any transfer, whether or not for
value, except for certain permitted transfers described in our certificate of incorporation, including transfers to family members, trusts
solely for the benefit of the stockholder or their family members, distributions or transfers of shares out to owners of a stockholder,
or to partnerships, corporations, and other entities exclusively owned by the stockholder or their family members, as well as affiliates,
subject to certain exceptions. Once converted or transferred and converted into Class A Common Stock, the Class B Common Stock may not
be reissued.
Rights and Preferences. Holders
of our common stock have no preemptive, conversion or subscription rights, and there will be no redemption or sinking funds provisions
applicable to our common stock. The rights, preferences and privileges of the holders of our common stock will be subject to, and may
be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in
the future.
Fully Paid and Nonassessable. All
of our outstanding shares of Class A Common Stock and Class B Common Stock are, and any shares of Class A Common Stock offered hereby
will, when issued be, fully paid and nonassessable.
Listing.
Our Class A Common Stock is listed on the NASDAQ Capital
Market under the symbol “LGVN.”
Transfer Agent and Registrar
The transfer agent and registrar for our Class A Common
Stock is Colonial Stock Transfer Company, Inc.
Preferred Stock
Our board of directors has the authority, without
further action by the stockholders, to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences,
privileges, and restrictions thereof. The issuance of preferred stock could adversely affect the voting power of holders of common stock
and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred
stock could have the effect of delaying, deferring or preventing change in our control or other corporate action. We have no present plan
to issue any shares of preferred stock.
Prior to the issuance of shares of each series of preferred stock,
the board of directors is required by the Delaware General Corporation Law (“DGCL”) and our certificate of incorporation to
adopt resolutions and file a certificate of designations with the Secretary of State of the State of Delaware. The certificate of designations
fixes for each class or series the designations, powers, preferences, rights, qualifications, limitations and restrictions, including,
but not limited to, some or all of the following:
| ● |
the number of shares constituting that series and the distinctive designation of that series, which number may be increased or decreased (but not below the number of shares then outstanding) from time to time by action of the board of directors; |
| ● |
the dividend rate and the manner and frequency of payment of dividends on the shares of that series, whether dividends will be cumulative, and, if so, from which date; |
| ● |
whether that series will have voting rights, in addition to any voting rights provided by law, and, if so, the terms of such voting rights; |
| ● |
whether that series will have conversion privileges, and, if so, the terms and conditions of such conversion, including provision for adjustment of the conversion rate in such events as the board of directors may determine; |
| ● |
whether or not the shares of that series will be redeemable, and, if so, the terms and conditions of such redemption; |
| ● |
whether that series will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of such sinking fund; |
| ● |
whether or not the shares of the series will have priority over or be on a parity with or be junior to the shares of any other series or class in any respect; |
| ● |
the rights of the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation, and the relative rights or priority, if any, of payment of shares of that series; and |
| ● |
any other relative rights, preferences and limitations of that series. |
All shares of preferred stock offered hereby will,
when issued, be fully paid and non-assessable, including shares of preferred stock issued upon the exercise of preferred stock warrants
or subscription rights, if any.
Although our board of directors has no intention at
the present time of doing so, it could authorize the issuance of a series of preferred stock that could, depending on the terms of such
series, impede the completion of a merger, tender offer or other takeover attempt.
Anti-Takeover Provisions
Some provisions of Delaware law and our certificate
of incorporation and our bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer;
an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible
that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider
to be in their best interests or in our best interests, including transactions that provide for payment of a premium over the market price
for our shares.
These provisions, summarized below, are intended to
discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to
acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our
potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages
of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.
Dual Class Stock. As described above our
certificate of incorporation provides for a dual class common stock structure, which provides holders of our Class B Common Stock
with significant influence over matters requiring stockholder approval, including the election of directors and significant corporate
transactions, such as a merger or other sale of our company or its assets.
Stockholder Meetings. Our bylaws provide
that a special meeting of stockholders may be called only by the chairman of our board of directors, our chief executive officer or president
(in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors.
Requirements for Advance Notification of Stockholder
Nominations and Proposals. Our bylaws establish advance notice procedures with respect to stockholder proposals to be brought
before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction
of our board of directors or a committee of our board of directors.
Elimination of Stockholder Action by Written Consent. Any
action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be taken
by written consent.
Staggered Board. Our board of directors
is divided into three classes. The directors in each class serve a three-year term, with one class being elected each year by our stockholders.
This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting
to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.
Removal of Directors. Our certificate
of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and,
in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding
shares of stock entitled to vote in the election of directors.
Stockholders Not Entitled to Cumulative Voting. Our
certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders
of a majority of the outstanding shares of our common stock entitled to vote in any election of directors will be able to elect all of
the directors standing for election, if they choose. Further, as discussed above, holders of our Class B Common Stock will be entitled
to five (5) votes for each share of Class B Common Stock held by them, including with respect to election of directors.
Choice of Forum. Our certificate of incorporation
provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will
be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of
breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, (3) any
action asserting a claim against us arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the
Court of Chancery of the State of Delaware, (4) any action to interpret, apply, enforce or determine the validity of our certificate of
incorporation or bylaws, or (5) any action asserting a claim governed by the internal affairs doctrine. Under our certificate of incorporation,
this exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the
Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction.
For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability
or duty created by the Securities Act, the Exchange Act, or the rules and regulations thereunder.
Our certificate of incorporation further provides
that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause
of action arising under the Securities Act. Our certificate of incorporation also provides that any person or entity holding, purchasing
or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to these choice
of forum provisions. It is possible that a court of law could rule that the choice of forum provision contained in our certificate of
incorporation are inapplicable or unenforceable if they are challenged in a proceeding or otherwise.
Amendment of Charter Provisions. The amendment
of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock and the
provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares
of stock entitled to vote thereon.
The provisions of Delaware law, and our certificate
of incorporation and bylaws, could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they
may also inhibit temporary fluctuations in the market price of our Class A common stock that often result from actual or rumored
hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management.
It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be
in their best interests.
Section 203 of the Delaware General Corporation
Law. We are subject to Section 203 of the DGCL, which prohibits persons deemed to be “interested stockholders” from
engaging in a “business combination” with a publicly held Delaware corporation for three years following the date these persons
become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder
was, approved in a prescribed manner or another prescribed exception applies. Generally, an “interested stockholder” is a
person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder
status did own, 15% or more of a corporation’s voting stock. Generally, a “business combination” includes a merger,
asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision
may have an anti-takeover effect with respect to transactions not approved in advance by our board of directors.
Limitations on Liability and Indemnification Matters.
Our certificate of incorporation limits our directors’ liability to the fullest extent permitted under Delaware law, which prohibits
our certificate of incorporation from limiting the liability of our directors for the following:
| ● |
any breach of the director’s duty of loyalty to us or our stockholders; |
| |
|
| ● |
acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; |
| |
|
| ● |
unlawful payment of dividends or unlawful stock repurchases or redemptions; or |
| |
|
| ● |
any transaction from which the director derived an improper personal benefit. |
If Delaware law is amended to authorize corporate
action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or
limited to the fullest extent permitted by Delaware law, as so amended.
Our bylaws provide that we will indemnify our directors
and officers to the fullest extent permitted under Delaware law and that we shall have the power to indemnify our employees and agents
to the fullest extent permitted by law. Our bylaws also permit us to secure insurance on behalf of any officer, director, employee or
other agent for any liability arising out of his or her actions in this capacity, regardless of whether we would have the power to indemnify
such person against such expense, liability or loss under the DGCL.
We have also entered into separate indemnification
agreements with our directors and executive officers, in addition to indemnification provided for in our bylaws. These agreements, among
other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement amounts
incurred by such persons in any action or proceeding arising out of this person’s services as a director or executive officer or
at our request. We believe that these provisions in our certificate of incorporation and bylaws and indemnification agreements are necessary
to attract and retain qualified persons as directors and executive officers. The above description of the limitation of liability and
indemnification provisions of our certificate of incorporation, our bylaws and our indemnification agreements is not complete and is qualified
in its entirety by reference to these documents, each of which have been filed as exhibits with the SEC.
DESCRIPTION OF WARRANTS
As of April 1, 2022, we have issued and outstanding
warrants to purchase up to 1,271,399 shares of our Class A Common Stock, in the aggregate. Our outstanding warrants are currently exercisable
at a weighted average exercise price of $17.26 per share.
The following description, together with the additional
information we may include in any applicable prospectus supplement, summarizes the material terms and provisions of the warrants that
we may offer under this prospectus and any related warrant agreement and warrant certificate. While the terms summarized below will apply
generally to any warrants that we may offer, we will describe the specific terms of any series of warrants in more detail in the applicable
prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement
may differ from the terms described below. Specific warrant agreements will contain additional important terms and provisions and will
be incorporated by reference as an exhibit to the registration statement which includes this prospectus.
General
We may issue warrants for the purchase of Class A
Common Stock, and/or preferred stock in one or more series. We may issue warrants independently or together with Class A Common Stock,
and/or preferred stock, and the warrants may be attached to or separate from these securities.
We will evidence each series of warrants by warrant
certificates that we may issue under a separate agreement. We may enter into a warrant agreement with a warrant agent. Each warrant agent
may be a bank that we select which has its principal office in the United States. We may also choose to act as our own warrant agent.
We will indicate the name and address of any such warrant agent in the applicable prospectus supplement relating to a particular series
of warrants.
We will describe in the applicable prospectus supplement the terms of the
series of warrants, including:
| ● |
the offering price and aggregate number of warrants offered; |
| ● |
if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; |
| ● |
if applicable, the date on and after which the warrants and the related securities will be separately transferable; |
| ● |
in the case of warrants to purchase Class A Common Stock or preferred stock, the number or amount of shares of Class A Common Stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which and currency in which these shares may be purchased upon such exercise; |
| ● |
the manner of exercise of the warrants, including any cashless exercise rights; |
| ● |
the warrant agreement under which the warrants will be issued; |
| ● |
the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants; |
| ● |
anti-dilution provisions of the warrants, if any; |
| ● |
the terms of any rights to redeem or call the warrants; |
| ● |
any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; |
| ● |
the dates on which the right to exercise the warrants will commence and expire or, if the warrants are not continuously exercisable during that period, the specific date or dates on which the warrants will be exercisable; |
| ● |
the manner in which the warrant agreement and warrants may be modified; |
| ● |
the identities of the warrant agent and any calculation or other agent for the warrants; |
| ● |
if applicable, a discussion of any material United States federal income tax consequences of holding or exercising the warrants; |
| ● |
the terms of the securities issuable upon exercise of the warrants; |
| ● |
any securities exchange or quotation system on which the warrants or any securities deliverable upon exercise of the warrants may be listed or quoted; and |
| ● |
any other specific terms, preferences, rights or limitations of or restrictions on the warrants. |
Before exercising their warrants, holders of warrants
will not have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive dividends,
if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.
Exercise of Warrants
Each warrant will entitle the holder to purchase the
securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus
supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at
any time up to 5:00 P.M. eastern time on the expiration date that we set forth in the applicable prospectus supplement. After the close
of business on the expiration date, unexercised warrants will become void.
Holders of the warrants may exercise the warrants
by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required
exercise price by the methods provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate,
and in the applicable prospectus supplement, the information that the holder of the warrant will be required to deliver to the warrant
agent.
Upon receipt of the required payment and the warrant
certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the
applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants
represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants.
Enforceability of Rights by Holders of Warrants
Any warrant agent will act solely as our agent under
the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant.
A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility
in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings
at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the
holder of any other warrant, enforce by appropriate legal action the holder’s right to exercise, and receive the securities purchasable
upon exercise of, its warrants in accordance with their terms.
Warrant Agreement Will Not Be Qualified Under Trust
Indenture Act. No warrant agreement will be qualified as an indenture, and no warrant agent will be required to qualify as a trustee,
under the Trust Indenture Act. Therefore, holders of warrants issued under a warrant agreement will not have the protection of the Trust
Indenture Act with respect to their warrants.
Governing Law. Each warrant agreement and any
warrants issued under the warrant agreements will be governed by Delaware law.
Calculation Agent. Any calculations relating
to warrants may be made by a calculation agent, an institution that we appoint as our agent for this purpose. The prospectus supplement
for a particular warrant will name the institution that we have appointed to act as the calculation agent for that warrant as of the original
issue date for that warrant, if any. We may appoint a different institution to serve as calculation agent from time to time after the
original issue date without the consent or notification of the holders. The calculation agent’s determination of any amount of money
payable or securities deliverable with respect to a warrant will be final and binding in the absence of manifest error.
DESCRIPTION OF PURCHASE CONTRACTS
The following description summarizes the general features
of the purchase contracts that we may offer under this prospectus. Although the features we have summarized below will generally apply
to any future purchase contracts we may offer under this prospectus, we will describe the particular terms of any purchase contracts that
we may offer in more detail in the applicable prospectus supplement. The specific terms of any purchase contracts may differ from the
description provided below as a result of negotiations with third parties in connection with the issuance of those purchase contracts,
as well as for other reasons. Because the terms of any purchase contracts we offer under a prospectus supplement may differ from the terms
we describe below, you should rely solely on information in the applicable prospectus supplement if that summary is different from the
summary in this prospectus.
We will incorporate by reference into the registration
statement of which this prospectus is a part any purchase contract that we may offer under this prospectus before the sale of the related
purchase contract. We urge you to read any applicable prospectus supplement related to specific purchase contracts being offered, as well
as the complete instruments that contain the terms of the securities that are subject to those purchase contracts. Certain of those instruments,
or forms of those instruments, have been filed as exhibits to the registration statement of which this prospectus is a part, and supplements
to those instruments or forms may be incorporated by reference into the registration statement of which this prospectus is a part, from
reports we file with the SEC.
We may issue purchase contracts, including contracts
obligating holders to purchase from us, and for us to sell to holders, a specific or variable number of our securities at a future date
or dates. Alternatively, the purchase contracts may obligate us to purchase from holders, and obligate holders to sell to us, a specific
or varying number of our securities.
If we offer any purchase contracts, certain terms
of that series of purchase contracts will be described in the applicable prospectus supplement, including, without limitation, the following:
| ● |
the price of the securities or other property subject to the purchase contracts (which may be determined by reference to a specific formula described in the purchase contracts); |
| |
|
| ● |
whether the purchase contracts are issued separately, or as a part of units each consisting of a purchase contract and one or more of our other securities, including U.S. Treasury securities, securing the holder’s obligations under the purchase contract; |
| |
|
| ● |
any requirement for us to make periodic payments to holders or vice versa, and whether the payments are unsecured or pre-funded; |
| |
|
| ● |
any provisions relating to any security provided for the purchase contracts; |
| |
|
| ● |
whether the purchase contracts obligate the holder or us to purchase or sell, or both purchase and sell, the securities subject to purchase under the purchase contract, and the nature and amount of each of those securities, or the method of determining those amounts; |
| |
|
| ● |
whether the purchase contracts are to be prepaid or not; |
| |
|
| ● |
whether the purchase contracts are to be settled by delivery, or by reference or linkage to the value, performance or level of the securities subject to purchase under the purchase contract; |
| |
|
| ● |
any acceleration, cancellation, termination or other provisions relating to the settlement of the purchase contracts; |
| |
|
| ● |
a discussion of certain U.S. federal income tax considerations applicable to the purchase contracts; |
| |
|
| ● |
whether the purchase contracts will be issued in fully registered or global form; and |
| |
|
| ● |
any other terms of the purchase contracts and any securities subject to such purchase contracts. |
DESCRIPTION OF UNITS
We may issue units comprised of one or more of the
other securities described in this prospectus or in any prospectus supplement in any combination. Each unit will be issued so that the
holder of the unit is also the holder, with the rights and obligations of a holder, of each security included in the unit. The unit certificate
may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified
date or upon the occurrence of a specified event or occurrence.
The applicable prospectus supplement will describe:
| ● |
the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; |
| |
|
| ● |
any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and |
| |
|
| ● |
whether the units will be issued in fully registered or global form. |
PLAN OF DISTRIBUTION
We may sell the securities being offered pursuant
to this prospectus to or through underwriters, through dealers, through agents, or directly to one or more purchasers or through a combination
of these methods. The applicable prospectus supplement will describe the terms of the offering of the securities, including:
| ● |
the name or names of any underwriters, and if required, any dealers or agents; |
| ● |
the purchase price of the securities and the proceeds we will receive from the sale; |
| ● |
any underwriting discounts or agency fees and other items constituting underwriters’ or agents’ compensation; |
| ● |
any discounts or concessions allowed or reallowed or paid to dealers; and |
| ● |
any securities exchange or market on which the securities may be listed or traded. |
We may distribute the securities from time to time in one or more public
or private transactions at:
| ● |
a fixed price or prices, which may be changed; |
| ● |
market prices prevailing at the time of sale; |
| ● |
prices related to such prevailing market prices; |
| ● |
negotiated prices; or |
| |
|
| ● |
through any other method permitted by applicable law and described in the applicable prospectus supplement. |
Only underwriters named in the prospectus supplement
are underwriters of the securities offered by such prospectus supplement. If underwriters are used in an offering, we will execute an
underwriting agreement with such underwriters and will specify the name of each underwriter and the terms of the transaction (including
any underwriting discounts and other terms constituting compensation of the underwriters and any dealers) in a prospectus supplement.
The securities may be offered to the public either through underwriting syndicates represented by managing underwriters or directly by
one or more investment banking firms or others, as designated. If an underwriting syndicate is used, the managing underwriter(s) will
be specified on the cover of the prospectus supplement. If underwriters are used in the sale, the offered securities will be acquired
by the underwriters for their own accounts and may be resold from time to time in one or more transactions, including negotiated transactions,
at a fixed public offering price or at varying prices determined at the time of sale. Any public offering price and any discounts or concessions
allowed or reallowed or paid to dealers may be changed from time to time. Unless otherwise set forth in the prospectus supplement, the
obligations of the underwriters to purchase the offered securities will be subject to conditions precedent, and the underwriters will
be obligated to purchase all of the offered securities, if any are purchased.
We may grant to the underwriters options to purchase
additional securities to cover over-allotments, if any, at the public offering price, with additional underwriting commissions or discounts,
as may be set forth in a related prospectus supplement. The terms of any over-allotment option will be set forth in the prospectus supplement
for those securities. If we use a dealer in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement,
we will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to
be determined by the dealer at the time of resale. The names of the dealers and the terms of the transaction will be specified in a prospectus
supplement.
We may sell the securities directly or through agents
we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions
we will pay the agent in the prospectus supplement. We may authorize agents or underwriters to solicit offers by institutional investors
to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts
providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions
we must pay for solicitation of these contracts in the prospectus supplement.
In connection with the sale of the securities, underwriters,
dealers or agents may receive compensation from us or from purchasers of the securities for whom they act as agents, in the form of discounts,
concessions or commissions. Underwriters may sell the securities to or through dealers, and those dealers may receive compensation in
the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom they may act as agents.
Underwriters, dealers and agents that participate in the distribution of the securities, and any institutional investors or others that
purchase securities directly for the purpose of resale or distribution, may be deemed to be underwriters, and any discounts or commissions
received by them from us and any profit on the resale of the common stock by them may be deemed to be underwriting discounts and commissions
under the Securities Act.
We may provide agents, underwriters and other purchasers
with indemnification against particular civil liabilities, including liabilities under the Securities Act, or contribution with respect
to payments that the agents, underwriters or other purchasers may make with respect to such liabilities. Agents and underwriters may engage
in transactions with, or perform services for, us in the ordinary course of business.
To facilitate the public offering of a series of securities,
persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect the market price of the
securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the
offering of more securities than have been sold to them by us in exercising the over-allotment option granted to those persons. In addition,
those persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing
penalty bids, whereby selling concessions allowed to underwriters or dealers participating in any such offering may be reclaimed if securities
sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain
the market price of the securities at a level above that which might otherwise prevail in the open market. Such transactions, if commenced,
may be discontinued at any time. We make no representation or prediction as to the direction or magnitude of any effect that the transactions
described above, if implemented, may have on the price of our securities.
Unless otherwise specified in the applicable prospectus
supplement, any Class A Common Stock sold pursuant to a prospectus supplement will be eligible for listing on The NASDAQ Capital Market,
subject to official notice of issuance. Any underwriters to whom securities are sold by us for public offering and sale may make a market
in the securities, but such underwriters will not be obligated to do so and may discontinue any market making at any time without notice.
In order to comply with the securities laws of some
states, if applicable, the securities offered pursuant to this prospectus will be sold in those states only through registered or licensed
brokers or dealers. In addition, in some states securities may not be sold unless they have been registered or qualified for sale in the
applicable state or an exemption from the registration or qualification requirement is available and complied with.
LEGAL MATTERS
Unless the applicable prospectus supplement indicates
otherwise, the validity of the offered securities will be passed upon for us by Buchanan Ingersoll & Rooney PC.
EXPERTS
The financial statements of Longeveron Inc.
as of December 31, 2021 and 2020 and for each of the years in the two-year period ended December 31, 2021, incorporated by reference
in this prospectus and registration statement have been audited by MSL, P.A., an independent registered public accounting firm, as
set forth in their report thereon, appearing in the Longeveron Inc. Annual Report on Form 10-K for the year ended December 31, 2021,
and are included in this prospectus and the registration statement of which this prospectus is a part in reliance upon such report given upon the authority of that firm as experts in accounting and auditing.
WHERE YOU CAN FIND ADDITIONAL INFORMATION ABOUT
US
We are required to file annual and quarterly reports,
current reports, proxy statements, and other information with the SEC. We make these documents publicly available, free of charge, on
our website at www.longeveron.com as soon as reasonably practicable after filing such documents with the SEC. You can read our
SEC filings, including the registration statement, on the SEC’s website at http://www.sec.gov.
This prospectus is part of a registration statement
we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and
regulations. You should review the information and exhibits in the registration statement for further information about us and the securities
we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we
otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings and the exhibits attached
thereto. You should review the complete document to evaluate these statements. We will provide to each person, including any beneficial
owner, to whom a prospectus is delivered, a copy of any or all of the information that has been incorporated by reference in the prospectus
but not delivered with the prospectus. We will provide this information upon oral or written request, free of charge. Any requests for
this information should be made by calling or sending a letter to the Secretary of the Company, c/o Longeveron Inc., 1951 NW 7th
Avenue, Suite 520, Miami, Florida 33136. Our telephone number is (305) 909-0840.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC’s rules allow us to “incorporate
by reference” information into this prospectus, which means that we can disclose important information to you by referring you to
another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and
subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in
this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this
prospectus to the extent that a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies
or replaces that statement.
The following documents filed by us with the Securities
and Exchange Commission are incorporated by reference in this prospectus:
| ● | Annual Report on Form 10-K for the fiscal year ended December
31, 2021, filed on March 11, 2022; and |
| ● | Our Current Report on Form 8-K filed with the SEC on March 25, 2022 and April 5, 2022 (in each case, except for information contained therein which is furnished rather than filed); and |
We also incorporate by reference all documents
we file (other than documents or portions of documents deemed to be furnished pursuant to the Exchange Act) under Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act (a) after the initial filing date of the registration statement of which this prospectus is a part and
before the effectiveness of the registration statement, and (b) after the effectiveness of the registration statement and before the filing
of a post-effective amendment that indicates that the securities offered by this prospectus have been sold or that deregisters the securities
covered by this prospectus then remaining unsold. Any statement contained herein or in a document incorporated or deemed to be incorporated
by reference herein shall be deemed to be modified or superseded for purposes hereof or of the related prospectus supplement to the extent
that a statement in any other subsequently filed document which is also incorporated or deemed to be incorporated herein modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a
part of this prospectus.
$50,000,000
Class A Common Stock
Preferred Stock
Warrants
Purchase Contracts
Units
PROSPECTUS
, 2022
We have not authorized any dealer, salesperson
or other person to give any information or represent anything not contained in or incorporated by reference into this prospectus. You
must not rely on any unauthorized information. If anyone provides you with different or inconsistent information, you should not rely
on it. This prospectus does not offer to sell any shares in any jurisdiction where it is unlawful. Neither the delivery of this prospectus,
nor any sale made hereunder, shall create any implication that the information in this prospectus is correct after the date hereof.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The following table sets forth an estimate of
the fees and expenses relating to the issuance and distribution of the securities being registered hereby, other than underwriting discounts
and commissions, all of which shall be borne by the Company. All of such fees and expenses, except for the SEC Registration Fee, are
estimated:
| | |
Amount to
be paid | |
| SEC registration fee | |
$ | 4,635 | |
| FINRA filing fees | |
$ | (1 | ) |
| Printing expenses | |
$ | (1 | ) |
| Accounting fees and expenses | |
$ | (1 | ) |
| Legal fees and expenses | |
$ | (1 | ) |
| Miscellaneous | |
$ | (1 | ) |
| | |
| | |
| Total | |
$ | (1 | ) |
| (1) | These fees are calculated based
on the securities offered and the number of issuances and accordingly cannot be estimated at this time. |
Item 15. Indemnification of Officers and Directors
Section 145 of the DGCL provides that a corporation
has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation
for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys’
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit
or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or
proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed
to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was
unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect
to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the
extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all
of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery
or such other court shall deem proper.
Our certificate of incorporation provides that
we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit
or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become,
a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee
of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being
referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against
all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection
with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable
cause to believe his or her conduct was unlawful. Our certificate of incorporation provides that we will indemnify any Indemnitee
who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the
Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as
a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture,
trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including
attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection
with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue
or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication
but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to
the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses
(including attorneys’ fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee
under certain circumstances.
The Company maintains directors’ and
officers’ liability insurance. In addition, the Company has entered into agreements to indemnify its directors in addition
to the indemnification provided for in the Certificate of Incorporation and Bylaws. These agreements, among other things, indemnify the
Company’s directors for certain expenses (including attorneys’ fees), judgments, fines and settlement amounts incurred
by such person in any action or proceeding, including any action by or in the right of the Company, on account of services by that person
as a director or officer of the Company, or as a director or officer of any subsidiary of the Company, or as a director or officer of
any other company or enterprise that the person provides services to at the request of the Company.
Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to our directors, officers or controlling persons, we have been advised that in the opinion
of the SEC this indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
Item 16. Exhibits
Exhibit
Number |
|
Description of Exhibit |
| |
|
|
| 1.1* |
|
Form of underwriting agreement |
| |
|
|
| 2.1 |
|
Plan of Conversion, incorporated by reference to Exhibit 2.1 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2021 |
| |
|
|
| 2.2 |
|
Certificate of Conversion of Longeveron LLC, incorporated by reference to Exhibit 2.2 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2021 |
| |
|
|
| 4.1 |
|
Certificate of Incorporation of Longeveron Inc., incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-8 filed on February 16, 2021 |
| |
|
|
| 4.2 |
|
Bylaws of Longeveron Inc., incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-8 filed on February 16, 2021 |
| |
|
|
| 4.3 |
|
Specimen Class A Common Stock Certificate evidencing the shares of Class A Common Stock, incorporated by reference to Exhibit 4.1 on Registrant’s Registration Statement No. 333-252234 filed February 3, 2021 |
| |
|
|
| 4.4 |
|
Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. Incorporated by reference to Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K filed on March 11, 2022 |
| |
|
|
| 4.5 |
|
Underwriter Warrants issued February 17, 2021, incorporated by reference to Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2021 |
| |
|
|
| 4.6 |
|
Form of Purchaser Warrant, incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed December 3, 2021 |
| |
|
|
| 4.7 |
|
Form of Representative Warrant, incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed December 3, 2021 |
| |
|
|
| 4.8* |
|
Form of specimen certificate for preferred stock of registrant, if any |
| |
|
|
| 4.9* |
|
Certificate of Designation for preferred stock, if any |
| |
|
|
| 4.10* |
|
Form of warrant agreement and warrant certificate, if any |
| |
|
|
| 4.11* |
|
Form of Purchase Contract Agreement |
| |
|
|
| 4.12* |
|
Form of unit certificate, if any |
| |
|
|
| 5.1 |
|
Opinion of Buchanan Ingersoll & Rooney PC, filed herewith |
| |
|
|
| 21.1 |
|
Subsidiaries of the Registrant, incorporated by reference to Exhibit 21.1 to the Registrant’s Registration Statement No. 333-252234 filed January 19, 2021 |
| |
|
|
| 23.1 |
|
Consent of Independent Registered Public Accounting Firm, filed herewith |
| |
|
|
| 23.2 |
|
Consent of Buchanan Ingersoll & Rooney PC (included in Exhibit 5.1) |
| |
|
|
| 24.1 |
|
Power of Attorney (included on signature page) |
| |
|
|
| 107 |
|
Filing Fee Table, filed herewith |
| * | To
be filed by amendment or incorporated by reference in connection with the offering of the
securities. |
Item 17. Undertakings.
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers
or sales are being made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by Section
10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or
events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually
or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent
change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration
statement;
(iii) To include any material information with
respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information
in the registration statement;
provided, however, that: paragraphs (a)(1)(i),
(a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of
prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
(2) That, for the purpose of determining any liability
under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a
post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(5) That, for the purpose of determining liability
under the Securities Act of 1933 to any purchaser:
(A) Each prospectus filed by the registrant pursuant
to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and
included in the registration statement; and
(B) Each prospectus required to be filed pursuant
to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant
to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall
be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used
after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in
Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a
new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates,
and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however,
that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated
or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as
to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
(6) That, for the purpose of determining liability
of the registrant under the Securities Act to any purchaser in the initial distribution of the securities:
The undersigned registrant undertakes that in
a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to
such purchaser:
(i) Any preliminary prospectus or prospectus of
the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
(ii) Any free writing prospectus relating to the
offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
(iii) The portion of any other free writing prospectus
relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of
the undersigned registrant; and
(iv) Any other communications that is an offer
in the offering made by the undersigned registrant to the purchaser.
(b) The undersigned registrant hereby undertakes
that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant
to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report
pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
(h) Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this
Registration Statement on Form S-3 and has duly caused this Registration Statement on Form S-3 to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Miami, State of Florida, on the fifth day of April, 2022.
| |
By: |
/s/ Geoff Green |
| |
Name: |
Geoff Green |
| |
Title: |
Chief Executive Officer
(principal executive officer) |
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose
signature appears below constitutes and appoints Geoff Green, James Clavijo and Paul Lehr and each of them acting individually, his
true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead,
in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to
sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant
to Rule 462(b) promulgated under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same,
with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done
in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that
such attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue
hereof.
Pursuant to the requirements of the Securities
Act of 1933, as amended, this registration statement has been signed below by the following persons on behalf of the registrant in the
capacities and on the dates indicated.
| Signature |
|
Title |
|
Date |
| |
|
|
|
|
| /s/ Geoff Green |
|
Chief Executive Officer |
|
April 5, 2022 |
| Geoff Green |
|
(principal executive officer) |
|
|
| |
|
|
|
|
| /s/ James Clavijo |
|
Chief Financial Officer |
|
April 5, 2022 |
| James Clavijo |
|
(principal financial and accounting officer) |
|
|
| |
|
|
|
|
| /s/ Joshua Hare |
|
Chairman of the Board |
|
April 5, 2022 |
| Joshua Hare |
|
|
|
|
| |
|
|
|
|
| /s/ Erin Borger |
|
Director |
|
April 5, 2022 |
| Erin Borger |
|
|
|
|
| |
|
|
|
|
| /s/ Todd Girolamo |
|
Director |
|
April 5, 2022 |
| Todd Girolamo |
|
|
|
|
| |
|
|
|
|
| /s/ Neil Hare |
|
Director |
|
April 5, 2022 |
| Neil Hare |
|
|
|
|
| |
|
|
|
|
| /s/ Douglas Losordo |
|
Director |
|
April 5, 2022 |
| Douglas Losordo |
|
|
|
|
| |
|
|
|
|
| /s/ Cathy Ross |
|
Director |
|
April 5, 2022 |
| Cathy Ross |
|
|
|
|
| |
|
|
|
|
| /s/ Don Soffer |
|
Director |
|
April 5, 2022 |
| Don Soffer |
|
|
|
|
| |
|
|
|
|
| /s/ Rock Soffer |
|
Director |
|
April 5, 2022 |
| Rock Soffer |
|
|
|
|
| |
|
|
|
|
| /s/ Ursula Ungaro |
|
Director |
|
April 5, 2022 |
| Ursula Ungaro |
|
|
|
|
II-5
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Nov 2023 to Nov 2024
